Sweden
Cinclus Pharma is a biotechnology startup based in Sweden, founded in 2014, that focuses on developing small molecules for the treatment of gastric acid related diseases. The company's lead drug candidate, linaprazan glurate, is a Potassium Competitive Acid Blocker (P-CAB) designed to address Gastroesophageal reflux disease (GERD) and related conditions. With a team of pioneers in GERD treatment from companies such as Astra and AstraZeneca, Cinclus Pharma is advancing the development of linaprazan glurate, which has shown potential in early clinical studies to alleviate GERD symptoms and heal esophageal injuries more effectively than current pharmaceutical therapies.
The recent kr240.00M Venture Round investment on 20 May 2022 brought the participation of notable investors such as Irrus Investments, AP4, Eir Ventures, Trill Impact Ventures, and Linc AB. This substantial investment reflects confidence in Cinclus Pharma’s approach and the potential of its drug candidate. As a clinical stage pharma company, Cinclus Pharma’s focus on the clinical development of linaprazan glurate is integral to its growth strategy and the company's future success in the biotechnology, healthcare, and pharmaceutical industries.
With its headquarters in Sweden, Cinclus Pharma is strategically positioned in a region known for fostering global biotech innovations. The company's commitment to drawing from this heritage while leveraging contemporary science and a competent management team underscores its vision for sustained growth and impact in the field. By nurturing a motivated and competent team, Cinclus Pharma is poised to continue its journey of advancing innovative solutions for gastric acid related diseases.
